Del 1 - Resistance to Targeted Anti-Cancer Therapeutics

Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy

Targeted Therapies to Reverse Resistance

Inbunden, Engelska, 2013

Av Benjamin Bonavida

2 179 kr

Beställningsvara. Skickas inom 10-15 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

This volume gives the latest developments in on the mechanisms of cancer cell resistance to apoptotic stimuli, which eventually result in cancer progression and metastasis. One of the main challenges in cancer research is to develop new therapies to combat resistant tumors. The development of new effective therapies will be dependent on delineating the biochemical, molecular, and genetic mechanisms that regulate tumor cell resistance to cytotoxic drug-induced apoptosis. These mechanisms should reveal gene products that directly regulate resistance in order to develop new drugs that target these resistance factors and such new drugs may either be selective or common to various cancers. If successful, new drugs may not be toxic and may be used effectively in combination with subtoxic conventional drugs to achieve synergy and to reverse tumor cell resistance. The research developments presented in this book can be translated to produce better clinical responses to resistant tumors.

Produktinformation

Utgivningsdatum2013-04-27
Mått155 x 235 x 20 mm
Vikt582 g
FormatInbunden
SpråkEngelska
SerieResistance to Targeted Anti-Cancer Therapeutics
Antal sidor260
Upplaga2013
FörlagSpringer-Verlag New York Inc.
ISBN9781461470694

Tillhör följande kategorier

Onkologi inom Medicin
Patologi inom Medicin
Cellbiologi inom Naturvetenskap och teknik

Dr. Benjamin Bonavida is a professor at UCLA's David Geffen School of Medicine for the Department of Microbiology, Immunology, & Molecular Genetics. His other appointments include being a member of the Department of Defense Congressionally Directed Medical Research Program, Member of the National Cancer Institute's SPORE Program, member of the International Scientific Advisory Board of the Israel Cancer Research Foundation, to name a few. He's currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. In his career, he's published over 450 papers and reviews, and he's also edited two books with Springer in the past. For more information, please see the CV attached herewith.

Preface.- Multidrug resistance in cancer: a tale of ABC drug transporters.- Multidrug resistance: a role for membrane physics, pH and drug transporters.- Mechanisms and potential therapies for acquired resistance to inhibitors targeting the Raf or MEK kinases in cancer.- Mechanisms of resistance to targeted B-Raf therapies.- Role of β1integrins in the complication and drug resistance against lung cancer: targeting β1integrins to eradicate lung cancer.- Aldo-keto reductases as new therapeutic targets for colon cancer chemoresistance.- Overcoming drug resistance through elevation of ROS in cancer.- Cancer stem cells in resistance to cytotoxic drugs: implications in chemotherapy.- Two birds with a stone: molecular cancer therapy targeting signal transduction and DNA repair pathways.- Collateral sensitivity in drug-resistant tumor cells.- Human cancer resistance to trail-apoptotic pathway-targeted therapies.- The dark side of apoptosis.- Index.